BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

Tessera Therapeutics, the latest company to emerge from Flagship Pioneering, is developing a suite of gene editing tools based on mobile genetic elements that have the potential to create a broader range of genomic alterations...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...least one AAV vaccine has been tested in the clinic: an AAV2-based HIV vaccine from Targeted Genetics...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BioCentury | May 31, 2019
Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...as CMO and Lynn Purkins as VP of clinical operations. Johnson was interim COO of AmpliPhi Biosciences Corp....
...CEO: Niall O’Donnell Patents: Undisclosed Companies and Institutions Mentioned Allakos Inc. (NASDAQ:ALLK), San Carlos, Calif. AmpliPhi Biosciences Corp....
BioCentury | Apr 24, 2019
Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also...
BioCentury | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
BioCentury | Mar 1, 2019
Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how...
BioCentury | Feb 28, 2019
Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how...
BioCentury | Dec 14, 2018
Company News

Carter to fill Decicco's role until BMS finds new discovery head

With former head of discovery Carl Decicco gone, Bristol-Myers Squibb Co. (NYSE:BMY) will turn to Head of Discovery Chemistry and Molecular Technologies Percy Carter to lead discovery until it finds Decicco's replacement, according to company...
Items per page:
1 - 10 of 427
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

Tessera Therapeutics, the latest company to emerge from Flagship Pioneering, is developing a suite of gene editing tools based on mobile genetic elements that have the potential to create a broader range of genomic alterations...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...least one AAV vaccine has been tested in the clinic: an AAV2-based HIV vaccine from Targeted Genetics...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BioCentury | May 31, 2019
Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...as CMO and Lynn Purkins as VP of clinical operations. Johnson was interim COO of AmpliPhi Biosciences Corp....
...CEO: Niall O’Donnell Patents: Undisclosed Companies and Institutions Mentioned Allakos Inc. (NASDAQ:ALLK), San Carlos, Calif. AmpliPhi Biosciences Corp....
BioCentury | Apr 24, 2019
Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also...
BioCentury | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
BioCentury | Mar 1, 2019
Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how...
BioCentury | Feb 28, 2019
Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how...
BioCentury | Dec 14, 2018
Company News

Carter to fill Decicco's role until BMS finds new discovery head

With former head of discovery Carl Decicco gone, Bristol-Myers Squibb Co. (NYSE:BMY) will turn to Head of Discovery Chemistry and Molecular Technologies Percy Carter to lead discovery until it finds Decicco's replacement, according to company...
Items per page:
1 - 10 of 427